RECRUITING

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to compare the Spotlight AQ survey platform to the standard of care (SOC) pre-clinic assessment in adolescents \& young adults (16-25 years old) with Type 1 Diabetes (T1D). The main questions it aims to answer are: * Does using the Spotlight AQ survey in clinic decrease the A1c in the people who use it? * Do patients and healthcare providers like using the spotlight AQ survey? Participants will use the Spotlight AQ survey before coming in to two standard of care T1D clinic visits Participants will fill out surveys describing how they feel about using the Spotlight AQ survey. Some participants may be asked to do an interview to talk about how they feel about the Spotlight AQ survey.

Official Title

Spotlight AQ Randomized Controlled Trial of the Spotlight AQ Survey Platform to Evaluate Its' Efficacy and Applicability in a Clinic Setting.

Quick Facts

Study Start:2024-05-27
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06390371

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:16 Years to 25 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * 16-25 years old
  2. * Patients diagnosed with T1D for at least 6 months
  3. * On any diabetes treatment
  4. * Using a Continuous Glucose Monitor (CGM)
  5. * Willing/ able to use Spotlight AQ tool
  6. * Able to give verbal assent
  7. * Patients \& parents/caregiver speak English/ Spanish fluently
  8. * Patients in the Children's Mercy Kansas City Hospital or Boston Children's Hospital network
  1. * \<16 years old or \>25 years old
  2. * Mental illness that could seriously reduce their ability to participate in the study
  3. * Lack of capacity
  4. * In another T1D intervention study

Contacts and Locations

Study Contact

Priscilla Connell, MPH
CONTACT
816-601-4543
pcconnell@cmh.edu
Emily DeWit
CONTACT
913-515-5173
eldewit@cmh.edu

Principal Investigator

Mark Clements, MD
PRINCIPAL_INVESTIGATOR
Children's Mercy

Study Locations (Sites)

Children's Mercy
Kansas City, Missouri, 64111
United States

Collaborators and Investigators

Sponsor: Children's Mercy Hospital Kansas City

  • Mark Clements, MD, PRINCIPAL_INVESTIGATOR, Children's Mercy

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-27
Study Completion Date2025-12

Study Record Updates

Study Start Date2024-05-27
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Type 1 Diabetes Mellitus